@article{fdi:010078892,
  title = {{C}ounter-selection of antimalarial resistance polymorphisms by intermittent preventive treatment in pregnancy},
  author = {{H}uijben, {S}. and {M}acete, {E}. and {M}ombo-{N}goma, {G}. and {R}amharter, {M}. and {K}ariuki, {S}. and {D}esai, {M}. and {S}hi, {Y}. {P}. and {M}wangoka, {G}. and {M}assougbodji, {A}. and {C}ot, {M}ichel and {T}uikue {N}dam, {N}icaise and {U}beregui, {E}. and {G}upta, {H}. and {C}istero, {P}. and {A}ponte, {J}. {J}. and {G}onzalez, {R}. and {M}enendez, {C}. and {M}ayor, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground. {I}nnovative approaches are needed to limit antimalarial resistance evolution. {U}nderstanding the role of intermittent preventive treatment in pregnancy ({IPT}p) on the selection for resistance and the impact such selection has on pregnancy outcomes can guide future interventions. {M}ethods. {P}lasmodium fakiparum isolates (n = 914) from 2 randomized clinical trials were screened for pfmdrl copy number variation and pfcrt, pfmdrl, pfdhfr, and pfdhps resistance markers. {T}he trials were conducted between 2010 and 2013 in {B}enin, {G}abon, {K}enya, and {M}ozambique to establish the efficacy of {IPT}p-mefloquine ({MQ}) compared with {IPT}p-sulphadoxine-pyrimethamine ({SP}) in human immunodeficiency virus ({HIV})-uninfected and to {IPT}p-placebo in {HIV}-infected women. {R}esults. {I}n {HIV}-uninfected women, the prevalence of pfcrt mutants, pfdhfr/pfdhps quintuple mutants, and pfmdrl copy number was similar between women receiving {IPT}-{SP} and {IPT}p-{MQ}. {H}owever, prevalence of pfmdr1 polymorphism 86{Y} was lower in the {IPT}p-{MQ} group than in the {IPT}p-{SP} group, and within the {IPT}p-{MQ} group it was lower at delivery compared with recruitment. {N}o effect of {IPT}p-{MQ} on resistance markers was observed among {HIV}-infected women. {T}he carriage of resistance markers was not associated with pregnancy outcomes. {C}onclusions. {S}election of wild-type pfmdrl polymorphism {N}86 by {IPT}p-{MQ} highlights the strong selective pressure {IPT}p can exert and the opportunity for using negative cross-resistance in drug choice for clinical treatment and {IPT}p.},
  keywords = {intermittent preventive therapy ; malaria ; mefloquine ; pfmdr ; pregnancy ; {BENIN} ; {GABON} ; {KENYA} ; {MOZAMBIQUE}},
  booktitle = {},
  journal = {{J}ournal of {I}nfectious {D}iseases},
  volume = {221},
  numero = {2},
  pages = {293--303},
  ISSN = {0022-1899},
  year = {2020},
  DOI = {10.1093/infdis/jiz451},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078892},
}